Cogstate Ltd (ASX:CGS): Clinical Trial Contract Wins Expand Revenue Coverage

Aditi Sarkar

19 October 2026 11:11 PM AEDT

Cogstate Ltd (ASX:CGS): Clinical Trial Contract Wins Expand Revenue Coverage

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate recorded US$25.1 million of net sales contracts in 1Q27.
Five Phase 3 mood disorder trials accounted for more than 80% of the quarter’s contract value.
Total contracted revenue reached US$143.7 million at 30 September 2026.
Contracted FY27 revenue increased from US$48.3 million to US$56.8 million during the quarter.
Long-duration trials and a lower licence-fee contribution affected near-term revenue conversion.

Cogstate Ltd (ASX:CGS) develops digital cognitive assessments and provides clinical trial endpoint measurement and data-quality services for neuroscience research. Its business supports drug developers conducting complex central nervous system studies. For the quarter ended 30 September 2026, the company reported new contract awards spanning mood disorder trials and an increase in contracted revenue, highlighting how its clinical trial work is distributed across reporting periods.

New Clinical Trial Contracts

During 1Q27, Cogstate Ltd (ASX:CGS) executed US$25.1 million of net sales contracts, compared with US$21.42 million in the September quarter of FY26. The latest contract intake comprised work with pharmaceutical and biotechnology customers using the company’s technology and services to measure cognitive and other clinical endpoints.

Five Phase 3 studies involving bipolar disorder or depression, awarded across two customers, represented more than 80% of the quarter’s contract value. Cogstate (ASX:CGS) said its channel partnership model helped it secure these programmes by allowing sponsors to work with preferred clinical technology providers while accessing its specialist measurement services.

Contracted Revenue Across Reporting Periods

At 30 September 2026, Cogstate Ltd (ASX:CGS) reported US$143.7 million of total contracted revenue, including revenue recognised in 1Q27. This compared with US$101.8 million in the previous corresponding period, an increase of 41%. The total spans multiple financial periods and should not be confused with revenue already recognised in the financial statements.

Contracted revenue attributed to FY27 reached US$56.8 million, up from US$48.3 million at 30 June 2026. Of the current total, US$31.7 million related to the first half of FY27, compared with US$23.0 million for the corresponding period. The amount attributed to FY28 rose to US$39.7 million from US$31.4 million over the September quarter.

Contract Timing and Revenue Recognition

New contracts contributed US$8.4 million to contracted FY27 revenue, representing an in-year revenue yield of 34%. Cogstate (ASX:CGS) attributed the lower-than-usual first-quarter yield to licence fees representing 7% of contract sales, against its historical average range of 20%–25%, and to the proportion of longer Phase 3 studies.

Clinical trial contracts are recognised as revenue as predetermined milestones are achieved. A Phase 3 programme may run for four to five years, so contract signings and revenue recognition can occur in different financial periods. The company’s disclosed figures therefore distinguish orders secured from the value scheduled for recognition across several years.

Operating Considerations

Cogstate Ltd (ASX:CGS) depends on the timing of contract execution, customer trial enrolment and successful delivery of study milestones. Clinical programmes can change in scope or timing, affecting when contracted work becomes recognised revenue. The concentration of the September quarter’s contract intake in five trials across two customers is also relevant when assessing the period’s sales composition.

Key Insights

Cogstate (ASX:CGS) increased its contracted revenue position during the September 2026 quarter, with Phase 3 mood disorder studies contributing a substantial share of new work. The distinction between signed contracts, contracted revenue assigned to a financial period and recognised revenue remains central to understanding the results. Trial duration, licence fees and customer milestone schedules influence that distinction.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.